

COVID-19 CADTH Health Technology Review

Sotrovimab for the Treatment of COVID-19

This report was published on September 3, 2021.

To produce this report, CADTH used a modified approach to the selection, appraisal, and synthesis of the evidence to meet decision-making needs during the COVID-19 pandemic. Care has been taken to ensure the information is accurate and complete, but it should be noted that international scientific evidence about COVID-19 is changing and growing rapidly.

Version: 1.0
Publication Date: September 2021
Report Length: 7 Pages

Authors: Calvin Young, Carolyn Spry

Cite As: *Sotrovimab for the treatment of COVID-19*. Ottawa: CADTH; 2021 Sep. (CADTH health technology review: rapid review).

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca

Key Messages

- There is a lack of published peer-reviewed evidence regarding the clinical effectiveness of sotrovimab for the treatment of individuals with coronavirus disease 2019 (COVID-19).
- Results from an ongoing trial, which are expected later this year, should provide decision-makers with an increased understanding of the potential role of sotrovimab for the treatment of individuals with COVID-19.

Context and Policy Issues

Sotrovimab (also known as VIR-7831) is a human monoclonal antibody that binds the spike protein of severe acute respiratory syndrome coronavirus 2, the virus that causes COVID-19.¹ Engineered from an antibody isolated from a patient who recovered from severe acute respiratory syndrome in 2003,¹ this investigational therapeutic received an Emergency Use Authorization by the FDA in May 2021² and was authorized under Interim Order by Health Canada in July 2021.³ These regulatory decisions were based on preliminary results of the COVID-19 Monoclonal antibody Efficacy Trial — Intent to Care Early (COMET-ICE).^{2,4} The objective of the current report is to summarize the available evidence regarding the clinical effectiveness of sotrovimab for the treatment of COVID-19.

Research Question

What is the clinical effectiveness of sotrovimab for the treatment of coronavirus disease 2019 (COVID-19)?

Methods

Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, Embase, PubMed, the Cochrane Database of Systematic Reviews, the international HTA database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concept was sotrovimab. No filters were applied to limit retrieval by publication type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2019 and August 30, 2021.

Selection Criteria and Methods

One reviewer screened citations and selected studies. In the first level of screening, titles and abstracts were reviewed and potentially relevant articles were retrieved and assessed for inclusion. The final selection of full-text articles was based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Criteria	Description
Population	Individuals with confirmed COVID-19
Intervention	Sotrovimab (alone or in combination with other therapies)
Comparator	No treatment; placebo; other active treatments (e.g., casirivimab-imdevimab)
Outcomes	Clinical effectiveness (e.g., mortality, length of hospital stay, severity of clinical symptoms, viral load, safety [e.g., adverse events])
Study designs	Health technology assessments, systematic reviews, RCTs, and non-randomized studies

COVID-19 = coronavirus disease 2019; RCTs = randomized controlled trials.

Exclusion Criteria

Articles were excluded if they did not meet the selection criteria outlined in Table 1, they were duplicate publications, or were published prior to 2019.

Summary of Evidence

Quantity of Research Available

A total of 16 citations were identified in the literature search. Following screening of titles and abstracts, 13 citations were excluded and 3 potentially relevant reports from the electronic search were retrieved for full-text review. One potentially relevant publication was retrieved from the grey literature search for full-text review. Of these potentially relevant articles, 4 publications were excluded for various reasons, and no publications met the inclusion criteria and were included in this report. Appendix 1 presents the PRISMA⁵ flow chart of the study selection. Additional references of potential interest are provided in Appendix 2.

Summary of Findings

Clinical Effectiveness of Sotrovimab for the Treatment of COVID-19

No relevant evidence regarding the clinical effectiveness of sotrovimab for the treatment of individuals with confirmed COVID-19 was identified; therefore, no summary can be provided.


Conclusions and Implications for Decision- or Policy-Making

No relevant literature was identified regarding the clinical effectiveness of sotrovimab for the treatment of individuals with confirmed COVID-19. While results from a preplanned interim analysis⁶ from an ongoing randomized controlled trial⁴ investigating the effectiveness of sotrovimab (i.e., VIR-7831) versus placebo for the early treatment of non-hospitalized COVID-19 patients are available in a preprint, these results are preliminary and have not been peer-reviewed, and thus were not eligible for inclusion in this review. The final results of this clinical trial,⁴ as well as any subsequent studies, should provide decision-makers with some clarity with respect to the potential role of sotrovimab for the treatment of COVID-19.

References

1. Tuccori M, Ferraro S, Convertino I, et al. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. *MAbs*. 2020;12(1):1854149.
2. Coronavirus (COVID-19) update: FDA authorizes additional monoclonal antibody for treatment of COVID-19 [news release]. Silver Spring (MD): U.S. Food and Drug Administration; 2021: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-mono-clonal-antibody-treatment-covid-19>. Accessed 2021 Sep 1.
3. Regulatory decision summary - PrSotrovimab - Health Canada. Ottawa (ON): Government of Canada; 2021: <https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00836>. Accessed 2021 Sep 1.
4. Vir Biotechnology Inc. NCT0454060: VIR-7831 for the early treatment of COVID-19 in outpatients (COMET-ICE). *ClinicalTrials.gov*. Bethesda (MD): U.S. National Library of Medicine; 2020. Updated 2021 Aug 19: <https://clinicaltrials.gov/ct2/show/NCT0454060>. Accessed 2021 Aug 31.
5. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol*. 2009;62(10):e1-e34.
6. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Covid-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab [non-peer reviewed preprint]. *medRxiv*. 2021 May 28:doi: 10.1101/2021.1105.1127.21257096. <https://europepmc.org/article/PPR/PPR349174>. Accessed 2021 Aug 31.

Appendix 1: Selection of Included Studies



Appendix 2: References of Potential Interest

Previous CADTH Reports

Tocilizumab and sarilumab: evidence review and appraisal. Ottawa (ON): CADTH; 2021 Feb. (CADTH Health Technology Review). <https://cadth.ca/sites/default/files/covid-19/hc0014-001-tocilizumab-and-sarilumab-update1-mar25.pdf>

Review Articles

Case JB, Winkler ES, Errico JM, Diamond MS. On the road to ending the COVID-19 pandemic: are we there yet? *Virology*. 2021 May;557:70-85. [PubMed: PM33676349](#)

Goyal M, Tewatia N, Vashisht H, Jain R, Kumar S. Novel corona virus (COVID-19); Global efforts and effective investigational medicines: a review. *J Infect Public Health*. 2021 July;14(7):910-921. [PubMed: PM34119845](#)

Sun Y, Ho M. Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. *Antib Ther*. 2020 Dec;3(4):246-256. [PubMed: PM33912795](#)

Regulatory Documents and News Releases

Notice: Prescription Drug List (PDL): sotrovimab (COVID-19). Ottawa (ON): Health Canada: 2021: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/amendment-sotrovimab-covid-19.html>.

Drug and vaccine authorizations for COVID-19: list of authorized drugs, vaccines and expanded indications. Ottawa (ON): Health Canada: 2021: <https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/list-drugs.html>

Fact sheet for healthcare providers emergency use authorization (EUA) of sotrovimab. Silver Spring (MD): U.S. Food and Drug Administration: 2021: <https://www.fda.gov/media/149534/download>

Letter of authorization: sotrovimab. Silver Spring (MD): U.S. Food and Drug Administration: 2021: <https://www.fda.gov/media/149532/download>

Emergency Use Authorization (EUA) for sotrovimab 500 mg. Center for Drug Evaluation and Research (CDER) Review. Silver Spring (MD): U.S. Food and Drug Administration: 2021: <https://www.fda.gov/media/150130/download>

Paediatric investigation plan: sotrovimab. *EMA-002899-PIP01-20*. Amsterdam (NL): European Medicines Agency; 2021 Aug 19: <https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002899-pip01-20>.

TGA approves new COVID-19 treatment for use in Australia. Canberra (AU): Australian Department of Health: 2021 Aug 20: <https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/tga-approves-new-covid-19-treatment-for-use-in-australia>